Custom-Made vaccine targets cancer left behind after surgery

NCT ID NCT06529822

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 24 times

Summary

This early-stage trial tests a personalized cancer vaccine for people with bladder or gastroesophageal cancer who have tiny amounts of cancer still detectable after surgery. The vaccine is custom-made from each patient's unique tumor markers and aims to train the immune system to clear remaining cancer cells. The study enrolls 32 adults and focuses on safety, feasibility, and immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.